Nutex Health (NASDAQ:NUTX – Get Free Report) and Biodesix (NASDAQ:BDSX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.
Profitability
This table compares Nutex Health and Biodesix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nutex Health | 10.95% | 23.50% | 10.47% |
| Biodesix | -33.26% | -2,101.40% | -35.65% |
Earnings & Valuation
This table compares Nutex Health and Biodesix”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nutex Health | $875.26 million | 1.41 | $70.79 million | $12.94 | 13.88 |
| Biodesix | $88.50 million | 2.36 | -$35.26 million | ($4.06) | -4.96 |
Nutex Health has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Nutex Health, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Nutex Health and Biodesix, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nutex Health | 0 | 2 | 3 | 0 | 2.60 |
| Biodesix | 1 | 0 | 3 | 1 | 2.80 |
Nutex Health presently has a consensus price target of $243.33, indicating a potential upside of 35.52%. Biodesix has a consensus price target of $28.33, indicating a potential upside of 40.61%. Given Biodesix’s stronger consensus rating and higher probable upside, analysts clearly believe Biodesix is more favorable than Nutex Health.
Insider & Institutional Ownership
5.3% of Nutex Health shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 44.7% of Nutex Health shares are held by insiders. Comparatively, 23.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Nutex Health has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, Biodesix has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.
Summary
Nutex Health beats Biodesix on 8 of the 14 factors compared between the two stocks.
About Nutex Health
Nutex Health Inc. operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management. The Real Estate segment owns and owns and leases land and hospital building. The Hospital segment develops and operates a network of micro-hospitals, specialty hospitals and hospital outpatient departments which offers 24/7 care. It also provides operational and managerial services, including management, billing, collections, human resources and recruiting, legal, accounting, and marketing. In addition, the company offers healthcare services, including emergency room care, inpatient care, and behavioral health, as well as onsite imaging, such as CT scan, X-ray, MRI, ultrasound, etc.; certified and accredited laboratories; and onsite inpatient pharmacies. The company was founded in 2011 and is based in Houston, Texas.
About Biodesix
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Receive News & Ratings for Nutex Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutex Health and related companies with MarketBeat.com's FREE daily email newsletter.
